Drug design, often stated as rational drug design or just rational design, is that the inventive process of finding new medications supported the knowledge of a biological target. The drug is most ordinarily an organic small molecule that activates or inhibits the function of a biomolecule like a protein, which successively ends up in a therapeutic benefit to the patient. Within the most simple sense, drug design involves the planning of molecules that are complementary in shape and charge to the biomolecular target with which they interact and so will bind thereto. Drug design frequently but not necessarily relies on computer modeling techniques.

A biomolecular target (most commonly a protein or a nucleic acid) could be a key molecule involved during a particular metabolic or signaling pathway that's related to a selected disease condition or pathology or to the infectivity or survival of a microbial pathogen. Potential drug targets don't seem to be necessarily disease causing but must by definition be disease modifying. In some cases, small molecules are designed to boost or inhibit the target function within the specific disease modifying pathway. Small molecules (for example receptor agonists, antagonists, inverse agonists, or modulators; enzyme activators or inhibitors; or ion channel openers or blockers) are going to be designed that are complementary to the binding site of the target.

Gertrude Elion, working mostly with a gaggle of fewer than 50 people on purine analogues, contributed to the invention of the primary anti-viral; the primary immunosuppressant (azathioprine) that allowed human organ transplantation; the primary drug to induce remission of childhood leukemia; pivotal anti-cancer treatments; an anti-malarial; an anti-bacterial; and a treatment for gout.

The process of finding a brand new drug against a selected target for a specific disease usually involves high-throughput screening (HTS), wherein large libraries of chemicals are tested for his or her ability to change the target. For instance, if the target may be a novel GPCR, compounds are screened for his or her ability to inhibit or stimulate that receptor (see antagonist and agonist): if the target could be a protein kinase, the chemicals are going to be tested for his or her ability to inhibit that kinase. It's unlikely that an ideal drug candidate will emerge from these early screening runs. One amongst the primary steps is to screen for compounds that are unlikely to be developed into drugs; for instance compounds that are hits in almost every assay, classified by medicinal chemists as "pan-assay interference compounds", are removed at this stage, if they weren't already off from the chemical library.

Ideally, the computational method are going to be ready to predict affinity before a compound is synthesized and hence in theory only 1 compound has to be synthesized, saving enormous time and price. The fact is that present computational methods are imperfect and supply, at best, only qualitatively accurate estimates of affinity. In practice it still takes several iterations of design, synthesis, and testing before an optimal drug is discovered. Computational methods have accelerated discovery by reducing the amount of iterations required and have often provided novel structures.

Correspondence to
Dr. Derick Roy
Department of Pharmacy
skaggs school of Pharmacy and Pharmaceutical Sciences
Aurora
USA
E-mail: derickroye@hotmail.com